Beta-ARKnt Peptide for Heart Failure via GRK2 RGS Domain Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for heart failure lack effective targets for GRK2/βARK1, which is involved in the progression of heart failure, and there is a need for novel approaches to address the reduction in β-adrenergic receptor density and signaling pathways.
Innovation Solution
The development of a βARKnt peptide or nucleic acid encoding the peptide, delivered via an AAV vector, specifically targeting the GRK2-RGS domain to regulate β-adrenergic receptor density and provide cardio-protection during pressure-overload induced heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GRK2/βARK1 is targeted to restore GPCR levels and preserve cardiac function, then heart failure progression is slowed, but the complexity of identifying effective therapeutic targets increases due to GRK2's diverse functional roles
Solution Approach 1:
The invention segments the GRK2 protein into functional domains, specifically targeting the RGS domain (amino acids 485-620) with the βARKnt peptide. This segmentation allows selective inhibition of GRK2's harmful phosphorylation activity while preserving other functional roles, thereby simplifying therapeutic target identification while maintaining cardiac function preservation.
Solution Approach 2:
The βARKnt peptide acts as an intermediary that specifically binds to the GRK2 RGS domain, modulating its activity. This intermediary approach allows precise control over GRK2's diverse functions, enabling therapeutic intervention without the need to identify and target multiple different GRK2 interaction sites.
2Quantity of substance
If β-adrenergic receptor density is increased to improve cardiac signaling, then heart failure symptoms are alleviated, but the mechanisms for achieving this increase are limited by current therapy options
Solution Approach 1:
The invention delivers the βARKnt peptide or its encoding nucleic acid in advance to prevent the downregulation of β-adrenergic receptors. By administering this therapeutic agent before complete receptor loss occurs, the treatment preserves or increases receptor density, thereby improving cardiac signaling and providing versatility in treating heart failure at different stages.
Data Source
AI summary
This invention is generally related to novel compositions for treating or preventing heart failure. Specifically, the disclosure provides a composition comprising an amino-terminal domain of Beta.adrenergic receptor kinase-1 (Beta.ARKnt) peptide, or a nucleic acid encoding Beta.ARKnt. Further disclosed are methods of using the compositions for treating or preventing heart failure in a subject or for altering Beta.-adrenergic receptor (Beta.AR) density in a subject.